Novo Nordisk A/S Class B
No trades
Community discussions
From underperform to hold.
Price target at $73.00 (or 470 DKK)
Shorts closed.
as long as the neck hold bullish
Novo Nordisk has now received FDA approval and the news has started to spread beyond the trading crowd. It’s been picked up by mainstream media during the Christmas break – even people outside the market are reading about it. People like my dad and stock forums on FB.
The Nordic market has been closed for almost a week, so there’s likely pent-up demand. I wouldn’t be surprised to see a strong move on the reopen.
Looking ahead, January marks the start of a new phase. Pension funds typically rebalance and deploy capital at the beginning of the year, and Novo fits perfectly into that flow.
More importantly, a new revenue stream begins in January 2026 with the oral pill. That changes the long-term earnings profile. EPS should structurally move higher as this scales.
Short term momentum + long term fundamentals are finally aligning. People like Michael Burry are bullish on this sector too aswell as JP Morgan.
this is bull flag
next leg up incoming